Journal Logo

Reviews

Review of Current Machine Perfusion Therapeutics for Organ Preservation

Xu, Jing BS1; Buchwald, Julianna E. BS1; Martins, Paulo N. MD, PhD1

Author Information
doi: 10.1097/TP.0000000000003295
  • Free

Abstract

INTRODUCTION

Although over 120, 000 patients are currently on the waitlist for a lifesaving or life-extending organ in the United States, only 36, 529 transplants were performed in 2018.1 The shortage of available donor organs has pushed for the usage of marginal donor organs. However, the discard rate of organs remains high because of old age, previous organ damage, or predisposing condition and anticipated preservation injury. In addition, the usage of marginal donor grafts is also associated with a higher risk of developing posttransplant complications.2,3 Many of these complications are exacerbated by severe ischemia-reperfusion injury (IRI),4,5 which occurs when organs are preserved in a hypoxic static cold storage (SCS) environment, the traditional method of organ preservation. Therefore, organ machine perfusion (MP) has emerged as a promising alternative in kidney, liver, lung, heart, and pancreas preservation.5

Compared with SCS, MP allows for organs to be continuously perfused with oxygen and nutrients during the preservation period, thus limiting the period of cold ischemia. MP in most solid organ transplantation can be divided into normothermic MP (NMP; 35.5–37.5°C) and hypothermic MP (HMP; 1–8°C), and subnormothermic MP (20–35.5°C) has also been explored in some studies.6 Clinical trials involving NMP have shown promising results in lung, liver, and kidney transplantation. Keeping organs in a normothermic setting decreases the length of cold ischemia time and allows for oxygen and nutrients to be delivered to the organ. In addition, NMP allows easier organ assessment during the perfusion period. Clinical trials in HMP have been explored mostly in kidney transplantation, with some trials in liver transplantation as well. Compared with NMP, HMP is less complex and requires lower cost to implement, because it does not require oxygen carriers and all of the supplements necessary to keep optimal organ metabolism. In addition, HMP allows for some variables of organ assessment to be measured, such as flow rate and mitochondria oxidative function metabolites.7,8

Both NMP and HMP can act as platforms for injured organs to be repaired by the addition of therapeutic agents in the perfusate.9 Numerous MP therapeutic agents (MPTAs) have been tested in animal and human models, such as antiinflammatory agents, vasodilators, antiinfection agents, mesenchymal stem cells (MSCs), gene therapy agents (siRNA and shRNA), and defatting agents (Figure 1). This comprehensive review will examine and summarize all of the therapeutic agents used in MP of lung, liver, kidneys, and heart. Although MP has also been studied in pancreas10,11 transplantation, no MPTA studies have been published to date. Here, we specifically define MPTA as an agent that is added to the machine perfusate during ex situ MP in addition to standard perfusate (preservation solution) with the intention to modulate the graft. We are not considering here as MPTA insulin, heparin, glucose, basic nutrients, and oxygen.

FIGURE 1.
FIGURE 1.:
Machine perfusion therapeutic agent mechanisms of protection.

LUNG MACHINE PERFUSION THERAPEUTICS

Lung transplantation is the most effective treatment for end-stage lung disease.12 Despite the benefits of this lifesaving procedure, only 22.6% of the recovered lungs were used for transplantation in a 2017 report.13 This high discard rate can be partly attributed to the strict inclusion criteria for acceptable donor lungs. Lung transplantation recipients suffer from a high rate of primary graft failure due to IRI.14 Marginal lung grafts stored under traditional SCS are especially susceptible to IRI due to prolonged cold ischemia time.14 Recently, numerous clinical trials have demonstrated that marginal lungs transplanted after normothermic ex situ lung perfusion (ESLuP) have similar posttransplant outcomes compared with higher quality lungs preserved by SCS.15-17 A wide array of MPTAs have been investigated under NMP to further prevent the damage caused by IRI, some of which have even resulted in successful transplantation of would-be rejected lungs. These agents are summarized in Tables 1–3.

Mesenchymal Stem Cell and Related Therapies

MSCs are bone marrow–derived multipotent cells that secrete paracrine soluble factors with numerous therapeutic effects. The therapeutic potentials of MSCs have been explored in numerous diseases, such as myocardial infarction, sepsis, and diabetes. MSCs have also been shown in several in vivo lung models to ameliorate acute lung injury through modulation of the inflammatory response.52,53 Several laboratories have since then investigated the protective effects of adding MSCs into machine perfusate during lung preservation. MSC, MSC-derived microvesicles, and multipotent adult progenitor cells (another bone marrow–derived stem cell) have all been studies under ESLuP; these agents are summarized in Table 1.

TABLE 1.
TABLE 1.:
Stem cell therapy in lung machine perfusion

Lee et al19 first demonstrated the potential of using MSCs as an MPTA in 2009. In an ESLuP model, this laboratory treated–rejected human donor lungs injured by Escherichia coli endotoxin. The intrapulmonary administration of allogenic human MSCs improved alveolar fluid clearance (AFC), lung endothelial permeability, and pulmonary edema compared with ESLuP alone. Antiinflammatory effects were also demonstrated through a nonsignificant decrease in neutrophil cell count. In addition, the laboratory was able to show that the MSCs’ antiinflammatory effects were largely due to the secretion of keratinocyte growth factor, as silencing of this growth factor reduced the protective effects of MSC by nearly 80%.19

In a follow-up project, Lee et al20 used the same model to test donor lungs that were injured by live E. coli bacteria. Once again, improvements in AFC and antiinflammatory effects were observed in treated lungs. More interestingly, the MSCs also lowered the alveolar bacterial load in a dose-dependent manner and increased alveolar macrophage phagocytosis activity, thus demonstrating the antimicrobial effects of MSCs. McAuley et al,21 as a follow-up study, tested the therapeutic effects of MSCs using rejected donor lungs not injured by bacteria. Compared with ESLuP alone, MSC-treated lungs had significantly improved AFC to a normal level after 4 h of perfusion.

Mordant et al18 investigated the optimal delivery route and dosage of MSCs using an ESLuP model with porcine lungs. They concluded that the intravenous delivery of MSC at a dosage of 150 × 106 cells led to the most optimal decrease in interleukin-8 (IL-8), a proinflammatory cytokine. This dosage is nearly 30 times higher than that of the studies done by Lee et al and McAuley et al, who were able to show physiological improvements at a much lower dosage. More studies using the human lung models are needed to examine the true optimal dosage of MSCs in ESLuP.

Microvesicles derived from MSCs have also been investigated as a potential MPTA. MSC-derived microvesicles are circular fragments of membrane that contain biologically active materials, including mRNAs. In vivo models have shown that these microvesicles have similar therapeutic properties as MSCs.54 Additionally, the microvesicles have a lesser risk of causing tumor formation compared with MSCs. In a murine ESLuP model, Stone et al22 investigated the immunomodulatory mechanisms of MSC-derived microvesicles. A significant decrease in proinflammatory cytokines (IL-7, tumor necrosis factor alpha [TNF-α], CXCL1, and High Mobility Group Box 1) and a significant increase in antiinflammatory agents (keratinocyte growth factor, IL-10, and prostaglandin E2) were observed in the treated mice.

The therapeutic potentials of MSC-derived microvesicles have also been tested in 2 human lung models. Gennai et al23 used rejected human donor lungs to show that the administration of microvesicles significantly improved AFC and lung compliance. In a related study, Park et al24 administered microvesicles in human lungs that were damaged by E. coli, and these treated lungs had significantly lower bacterial load, in addition to superior AFC and endothelial permeability, compared with control.24

Multipotent adult progenitor cells are another type of bone marrow–derived stem cell type that has generated interest in the field of MP. Two ESLuP studies have shown that these cells can significantly reduce inflammatory markers in human26 and porcine25 models. However, no significant physiological differences were observed compared with ESLuP alone.

Lung Lavage and Surfactant Replacement

Gastric acid aspiration is a process that can lead to damage of the alveolar and capillary networks of the lung, and in turn, acute lung injury and aspiration pneumonitis.55 This acidic damage causes inflammation and surfactant dysfunction, both of which can contribute to primary graft dysfunction.56 Therefore, lungs damaged by aspiration is a common reason for organ rejection. Several laboratries have examined the potential of performing bronchoalveolar lavage, followed by exogeneous surfactant administration, during ESLuP to recover lungs injured by aspiration. Two types of exogenous bovine extract surfactants were used in these studies, both of which contained mainly surfactant proteins B and C (Curosurf and bovine lung extract surfactant).

Inci et al35 used a porcine ESLuP model with lungs injured by hydrochloric acid and pepsin to mimic gastric aspiration. Lungs that were immediately treated by lavage and surfactant had superior pulmonary vascular resistance (PVR), better oxygenation, and lower pulmonary edema. However, no significant differences were noted in the levels of inflammatory cytokines.

In the clinical setting, aspiration damage is typically diagnosed via radiology and histology many hours after its onset. To account for this, Khalifé-Hocquemiller et al37 treated aspiration-injured lungs after 24 h of gastric juice-induced injury. Once again, treated lungs demonstrated superior PVR and oxygenation. In addition, significantly lower levels of IL-6 were also noted in the treated lungs;37 this additional finding demonstrates lavage and surfactant administration have a more prominent protective effect in lungs damaged by aspiration followed by warm ischemia.

The above results were further corroborated by 2 porcine transplantation models. Porcine lungs were damaged by aspiration injury followed by 436 and 638 h of ESLuP, and these lungs were then transplanted into recipient pigs and reperfused for 4 h. Lavage and surfactant administration were performed immediately before ESLuP. In both studies, treated lungs demonstrated superior oxygenation, higher compliance, and lower IL-1β and IL-6 levels in the blood. Nakajima et al38 specifically tested the minimal surface tension of isolated surfactant using a biophysical functional analysis and demonstrated that surfactant from treated lungs had significantly lower surface tension. In summary, exogenous surfactant, administered after bronchoalveolar lavage, is a promising MPTA that can be used to treat lungs damaged by gastric acid aspiration. Future studies involving human lung models are needed to confirm its efficacy.

Adenosine Receptor Agonist and Antagonists

Adenosine is naturally released by the body under conditions of cellular stress and mediates proinflammatory and antiinflammatory effects depending on the effector tissue and receptor type.57 The 4 known adenosine receptors are A1R, A2AR, A2BR, and A3R, all of which are expressed on human lungs. Prior studies using animal models have already demonstrated A1R, A2AR, and A3R agonists’ role in attenuating IRI.58-60 Therefore, adenosine is one of the 2 major categories of small compounds being investigated as a potential MPTA, the other being β-adrenergic agonists (Table 2).

TABLE 2.
TABLE 2.:
Compounds targeting cell surface receptors in lung machine perfusion

Emaminia et al28 first examined the potential of using adenosine receptor agonists and antagonists as potential MPTAs during ESLuP. In a porcine model, retrieved lungs that were under 14 h of cold storage were treated with an A2AR agonist. Superior oxygenation, lower pulmonary edema, and inflammation were observed compared with lungs treated by ESLuP alone. In a subsequent study, Stone et al27 used a murine ESLuP model to examine specific gene expression profile changes that occur when A2AR agonists are added to the perfusate. They noticed a significant decrease in numerous inflammatory pathways, which led to reduced pulmonary edema, lower inflammatory cytokine levels, and superior lung function.27 Finally, in a porcine transplantation study, Huerter et al30 showed that the administration of A2AR agonists during ESLuP can improve oxygenation after transplantation.

In addition to A2AR agonists, 2 studies also investigated protective effects of using A2BR antagonists as a potential MPTA. A2BR has both proinflammatory and antiinflammatory effects, and its overall effect on lung injury depends on several factors, such as injury condition and type cells involved. Using murine and porcine ESLuP models, Huerter et al30 and Charles et al31 demonstrated that A2BR antagonists can alleviate damage caused by warm ischemia. The treated animals had superior lung compliance3031 and decreased inflammatory markers.31

β-Adrenergic Agonists

Two types of β-adrenergic agonists have been tested as MPTAs in porcine and canine models. Salbutamol regulates fluid transport using sodium-dependent mechanisms and may be used as an MPTA to lower pulmonary edema during ESLuP. Valenza et al32 showed that salbutamol infusion during ESLuP lowers the level of glucose in the perfusate. The concentration of glucose, shown in a prior study, is directly related to the degree of pulmonary edema.61 Furthermore, salbutamol also demonstrated vasodilatory effects that may improve oxygenation during ESLuP; treated lungs demonstrated lower PVR and compliance compared with control.32

Inhaled procaterol has also been shown to improve AFC through a cAMP-dependent mechanism.62 Transplantation models have previously shown that procaterol administration before procurement can alleviate warm-ischemic injury.6364 Therefore, Kondo et al33 investigated whether procaterol inhalation during ESLuP can have similar protective effects in a canine model. Treated lungs had improved arterial and airway pressure, in addition to lower PVR and higher lung compliance. In addition, total adenosine nucleotide levels were also observed after treatment, reflecting superior energy storage.33 Hijiya et al34 corroborated these results in a canine transplantation model, showing that transplanted lungs that were treated with procaterol had superior pulmonary functions and superior energy storage.

Fibrinolytic Agents

The postmortem microthrombi formation is another major cause for lung dysfunction and organ rejection, especially for donation after circulatory death (DCD) lungs. Fibrinolytic agents, such as urokinase, have been shown to have protective effects when infused into the donor lungs after cardiac arrest,6566 which lead to the possibility of using fibrinolytic agents as an MPTA. Inci et al39 used a porcine ESLuP model to show that urokinase, when added to the perfusate of ESLuP, can lower PVR, improve oxygenation, and lower pulmonary edema. The same group later used urokinase to treat a pair of human donor lungs that were damaged by pulmonary embolus. After 3 h of ESLuP with urokinase, significant improvements in compliance and oxygenation were observed, and the lungs were eventually transplanted without complications.40 In a similar manner, Machuca et al67 used a different thrombolytic agent, alteplase, to resuscitate a pair of human donor lungs that were rejected because of pulmonary embolism. Increased thrombolytic activity and decreased pulmonary arterial pressure were observed after 6 h of ESLuP, and the lungs were eventually transplanted without complications.

Drugs Targeting Microorganisms

The donor-to-host transmission of infectious microorganisms is a well-known threat to the immunosuppressed recipient, and ESLuP can act as a platform for treating lungs that are infected by bacteria and fungi. Andreasson et al42 first demonstrated this possibility by treating 18 marginal donor lungs with a broad-spectrum antibacterial agent, meropenem. After the discovery of fungi load in the first 3 pairs of lungs, an antifungal agent, amphotericin B, was also added to the perfusate. Significant reduction in bronchoalveolar bacterial and fungi load was observed in the treated lungs, and 4 infected lungs were able to be cured and transplanted without complications. Nakajima et al43 later investigated the possibility of using multiple antibacterial agents to treat rejected lungs with polymicrobial infections. In addition to a significant decrease in bacterial load in the bronchoalveolar lavage, numerous inflammatory markers, such as TNF-α and IL-1β, were also significantly reduced. In turn, the treated lungs also demonstrated superior compliance and oxygenation compared with control.43

A recent study demonstrated the potential of using light therapy as an MPTA to inactivate hepatitis C virus (HCV) in donor lungs using a modified ESLuP device. Up to 20% of lung donors in the United States are tested positive for HCV,68 and many of these donors are victims of overdose death—which means they have young and relatively healthy lungs. In a modified ESLuP model with an illumination device, Galasso et al44 used photodynamic therapy using methylene blue activated by red light irradiation to decrease HCV RNA levels by 98% in the perfusate and by 91% in lung tissue. UV C irradiation was also administered to a separate group of lungs and demonstrated similar virucidal effects.44 The results of this study have led to a prospective pilot clinical trial involving the transplantation of 22 HCV-positive lungs.69 Half of these lungs were treated with UV C irradiation, whereas the other half underwent ESLuP alone. Lungs treated with radiation demonstrated significantly lower recipient viral loads in blood within the first week after transplantation.69

Gene Therapy

The release of proinflammatory cytokines is a major cause of donor lung damage and rejection. A Toronto Group has conducted several studies using human and porcine models to investigate the possibility of using interleukin-10 (IL-10) gene therapy to suppress lung inflammation during ESLuP. Unlike in vivo gene therapy, in which gene delivery must be administered systemically, gene therapy during ESLuP allows for a more isolated delivery with less dosage and fewer systemic side effects. Cypel et al45 treated 10 discarded human donor lungs using adenoviral vector encoding human IL-10 (AdhIL-10) for 12 h. Treated lungs had superior oxygenation and lower PVR compared with control. In addition, a shift from proinflammatory to antiinflammatory cytokine production was observed.45 Yeung et al46 then used a porcine transplantation model to show that ex situ delivery of AdhIL-10 led to superior posttransplant lung function and less vector-related inflammation compared with in vivo delivery—demonstrating that ESLuP is a superior gene transduction platform. As a follow-up study, Machuca et al41 used a similar porcine model with a 7-d posttransplantation period to examine the long-term effects of using AdhIL-10 therapy. Treated lungs had superior posttransplant lung function and less inflammation, and interferon-γ suppression was demonstrated up to day 7.

Gene Modulating Agents

The complex process of IRI activates numerous genes that lead to cell apoptosis and tissue injury.4 Therefore, gene-silencing agents such as siRNA and shRNA have been explored in solid organ transplantation to reduce graft injury. In lung transplantation, in particular, the intratracheal delivery of siRNA and shRNA has been shown to alleviate IRI in in vivo murine models. These studies targeted proapoptotic and proinflammatory proteins, such as Fas, caspase, myeloid differentiation protein-2, and p38 mitogen-activated protein kinase.70 Although these results demonstrate the potential of RNA interference in lung transplantation, the in vivo intratracheal delivery of these agents is limited in the clinical setting, because it requires an invasive setup and requires several hours of intubation. ESLuP is a much more practical method to deliver RNA agents in an ex vivo and more targeted setting.

The ESLuP delivery of shRNAs using lentiviral vectors has already been explored to silence major histocompatibility complex antigens to avoid acute cellular rejection of donor lungs posttransplantation. Figueiredo et al47 showed that 2 h of ESLuP treatment with shRNAs targeting swine leukocyte antigens led to over 50% silencing of these endothelial antigens. No significant adverse effects were observed by the administration of lentivirus. This ESLuP method of delivering shRNAs can be applied to target antiapoptotic and antiinflammatory agents, such as those used in the aforementioned in vivo studies.

Other Therapeutic Agents

Numerous other MPTAs have been tested using murine and porcine models, but many of these results have yet been replicated using a transplantation or human lung donor models, and these are listed in Table 3. Briefly, several antiinflammatory agents, such as methylprednisolone,49 α1-antitrypsin,48 and neutrophil elastase inhibitors51 have been shown to improve pulmonary physiology and lower inflammatory markers in ESLuP porcine models. Hydrogen gas, a potent free-radical scavenger, has been used in ESLuP to improve pulmonary function and lower inflammation.71 Sphingo-1-phosphate, a regulator of endothelial barrier, has been shown to decrease endothelial vascular permeability.50 Although many of these agents will need to be further evaluated using transplantation and human lung models, they are promising therapeutic options in ESLuP.

TABLE 3.
TABLE 3.:
Major categories of machine perfusion therapeutics in lung transplantation (excluding MSC and small molecule agonists)

Liver Machine Perfusion Therapeutics

Liver preservation using MP is also an evolving field with numerous recent and ongoing clinical trials demonstrating its superior performance compared with SCS.72-76 Since the growth of new waitlist registrants continues to exceed the number of available donors,77 the usage of marginal livers (steatotic, elderly, and DCD livers) has been increasing. The benefits of ex situ liver machine perfusion (ESLiP) are especially apparent in the context of marginal liver transplants because ESLiP offers a platform for the reconditioning of these livers before transplant. In addition, numerous biomarkers in the perfusate and in bile, such as bilirubin, aspartate aminotransferase, alanine aminotransferase, and lactate, have been shown to be associated IRI and hepatobiliary injury.8,78-85

Several laboratries have already examined the potential of using MPTA during ESLiP, and these studies can be summarized in Table 4. Almost all studies were conducted under normothermic settings. Two studies were conducted under subnormothermic settings, and 1 study was under hypothermic setting. Two major categories of liver MPTA are defatting cocktails86-88 and vasodilators,89-92 both of which have been tested in multiple rat and porcine ESLiP and transplantation models. Additional studies involving human livers and clinical trials will need to be conducted to solidify these promising results.

TABLE 4.
TABLE 4.:
Major categories of machine perfusion therapeutics in liver transplantation

Defatting Agents

Steatotic livers account for a large portion of organ rejection because their usage is associated with a higher rate of primary graft dysfunction.100 Therefore, several labs have examined the possibility of reconditioning steatotic livers using ESLiP. Jamieson et al86 have shown that NMP alone can significantly reduce steatosis in a porcine ESLiP model. In this study, porcine liver steatosis was induced using streptozocin (a drug that causes hyperglycemia) and high-fat diet, and these liver were compared with nonfatty livers during 48 h of normothermic ESLiP. Fatty livers demonstrated higher perfusate triglyceride, glucose, and urea production during ESLiP compared with normal livers, which reflects a higher metabolic state. In addition, a significant reduction in lipid deposits was observed on histology.86 The addition of defatting cocktail during normothermic ESLiP was also investigated in a rodent model, by Nagrath et al.88 Livers treated with a combination of defatting agents demonstrated significantly decreased intracellular lipid content and increased lipid oxidation and export, after only 3 h of ESLiP. In addition, an increase in gene expression related to lipid mobilization was observed in the treated livers as well.88

Vasodilators

Injury to the microcirculation is a significant contributor to IRI and posttransplant dysfunction during liver transplantation.101 Liver sinusoidal endothelial cells, compared with hepatocytes, are known to be more prone to IRI during cold storage.101 In turn, the usage of prostaglandin E1 (PGE1) to improve the microcirculation has been examined by several studies. PGE1 is a potent vasodilator that also has antiplatelet and fibrinolytic effects. Hara et al90 first used PGE1 as an MPTA in an ex situ rodent model under normothermic conditions. Treated rodent livers had significantly improved bile production, in addition to decreased levels of liver injury markers: aspartate aminotransferase and alanine aminotransferase. Maida et al,91 from the same group, then corroborated these results using a rodent liver transplantation study using a similar setup. Treated rats had significantly higher survival rates, in addition to higher bile production and improved energy storage.

Prostacyclin, another naturally occurring vasodilating and antiplatelet agent, has also been examined as a potential MPTA in a porcine ESLiP model. Similar to PGE1, prostacyclin significantly improved bile production and lowered liver injury markers compared with ESLiP alone.92 Finally, 2 additional vasodilators, BQ123 (an endothelin receptor agonist) and verapamil (a calcium channel blocker), were studied in a porcine transplantation model by Echeverri et al.89 Treated livers demonstrated improved hepatic arterial flow and lower hepatocyte injury markers during ESLiP—however, no significant differences were observed 3 d after transplantation.89 This lack of significance may be due to the usage of relatively healthy donor livers, which did not undergo any warm-ischemic damage. A more significant outcome may be demonstrated in more marginal grafts.

Gene Modulation Agents

The usage of gene modulation agents, such as antisense oligonucleotides (ASOs) and siRNA in MP, is especially promising because it is much more targeted than systemic gene modulation, requiring less dosage and causing fewer side effects. Furthermore, it does not require viral transfection, which may adversely stimulate the immune system.95 Goldaracena et al93 first demonstrated the potential of using ASO to silence the virulence of HCV in a porcine ESLiP model. The ASO targeted miRNA-122, the most abundant miRNA in hepatocytes, which is a necessary factor for HCV replication. The silencing of miRNA has been shown to significantly decrease HCV activity in an in vitro model.93 Therefore, the ESLiP treatment of pretransplanted livers may have the potential to prevent HCV reinfections in patients who are HCV positive. Although this approach to prevent HCV reinfection is interesting, the high efficiency of current direct antiviral agents against HCV makes it less practical in the clinical setting.

Gillooly et al94 first demonstrated the successful siRNA uptake during ESLiP, under both normothermic and hypothermic conditions using a rodent model. The siRNA targeted the Fas receptor, whose activation contributes to a proapoptotic pathway that significantly contributes to IRI. Although the Fas pathway is only 1 potential target of gene modulation using siRNA, numerous other potential proinflammatory targets may be silenced to protect the liver.95

The same group, for example, also used siRNA targeting p53 to modulate apoptosis in an ESLiP rat model.95 Other potential targets include RelB, TNF-α, and proapoptotic caspases, which have already been demonstrated to have protective effects in murine models when delivered intravenously before the induction of ischemia.70

Other Therapeutic Agents

Two additional agents have been tested under normothermic ESLiP using rodent models. Rigo et al97 successfully demonstrated the uptake of human liver stem cell–derived extracellular vesicles during ex situ perfusion. In turn, treated livers had less histological damage and liver injury markers after 4 h of perfusion. In another study, enkephalin, a delta opioid agonist, was used during ESLiP to reduce injury caused by oxidative stress. Treated livers demonstrated significantly superior energy storage and less tissue injury markers.98

Therapeutic Agents Under Subnormothermic and Hypothermic Settings

Liu et al87 investigated using defatting cocktail in a subnormothermic ESLiP rodent model. Unlike normothermic ESLiP, subnormothermic (room temperature) ESLiP does not require temperature control and the addition of oxygen carriers, making it more practical in the clinical setting. However, the subnormothermic ESLiP time required to significantly increase perfusate lipid content was twice as long as that of normothermic ESLiP. In addition, no significant intracellular lipid content changes were observed.87 In comparison, normothermic ESLiP seems to be a more effective method of reducing steatosis.

Goldaracena et al96 used antiinflammatory agents during subnormothermic MP to minimize inflammatory damage during ESLiP in a porcine transplantation model. The authors chose a subnormothermic setting because of its inhibitory effects on Kupffer cells and inflammation compared with normothermic temperature. Although significantly lower aspartate aminotransferase and inflammatory cytokine levels were observed during ESLiP, no significant differences were observed during 3 d of reperfusion after transplantation. However, a significantly lower bilirubin level was observed in the treated groups after transplantation.

Finally, in a hypothermic ESLiP and transplantation model, Yu et al99 used mcc950, an nucleotide-binding domain leucine-rich repeat containing family pyrin domain containing 3 inflammasome inhibitor, as an antiinflammatory MPTA. Significantly lower inflammatory and injury markers were observed in treated livers after transplantation.

Kidney Machine Perfusion Therapeutics

Kidney transplant is the most effective treatment for end-stage renal failure, which affects nearly 100 000 new American patients per year.102 Deceased donor kidneys, especially DCD kidneys, are more susceptible to primary nonfunction and delayed graft function—thus the usage of hypothermic103 and normothermic104,105 ex situ kidney machine perfusion (ESKP) has been explored to protect these vulnerable kidney grafts during transplantation. Numerous functional parameters and biomarkers have been shown in NMP to be excellent predictors of kidney function during perfusion, including renal blood flow and urine output.106-108 Several biomarkers, such as glutathione S-transferase, have been examined in HMP as well.109 In addition, MPTAs have been studied in both temperatures of ESKP models; these agents have been summarized in Table 5.

TABLE 5.
TABLE 5.:
Major categories of machine perfusion therapeutics in kidney transplantation

Therapeutic Agents in Hypothermic Ex Situ Kidney Perfusion

MSC and its extracellular vesicles, known for their broad range of protective abilities in ESLuP (Table 1), have also been tested in a rodent ESKP model.116 After 40 min of warm ischemia, kidneys treated with MSC or its extracellular vesicles secreted lower markers of ischemic damage and glucose were in the efferent fluid, along with higher levels of pyruvate.116 This indicates an increase in energy substrate usage compared with kidneys preserved by ESKP alone. In addition, an upregulation of enzymes related to cell energy metabolism and ion membrane transport was demonstrated in the treated kidneys as well, which potentially explains the protective mechanism of MSC during ESKP.

Inhalation of carbon monoxide, a vasodilating and antiinflammatory agent, has been shown to have protective effects during kidney transplantation in animal models. Bhattacharjee et al117 created manganese-containing carbon monoxide-releasing molecules 401 to deliver carbon monoxide in a highly controlled manner. Using an ESKP porcine model, the group showed that carbon monoxide-releasing molecules 401 significantly improved renal function (increased renal blood flow and urine secretion) and lowered kidney damage markers on histology.

Microcirculatory failure due to thrombosis is a hallmark of IRI; in turn, 2 anticoagulative agents have been studied in ESKP porcine models. Sedigh et al118 treated explanted kidneys with a heparin conjugate during 20 h of ESKP. Superior kidney functions and lower kidney injury markers on histology were observed in treated kidneys. Hamaoui et al115 studied the effects of thrombalexin, a thrombin inhibitor, in both porcine and human kidney models. Treated porcine kidneys demonstrated significantly superior renal flow parameters and microvascular capillary perfusion. The treatment of 2 human kidneys demonstrated similar protective effects, in addition to lowering D-dimer and fibrinogen levels.115

Therapeutic Agents in Normothermic Ex Situ Kidney Perfusion

NMP, unlike HMP, occurs in higher metabolic state, which may allow kidney grafts to restore energy levels and heal damage caused by cold ischemic storage faster. Brasile et al114 showed that the addition of MSCs in normothermic ESKP can further accelerate the renal repair process. Using human kidney allografts, they showed that 24 h of perfusion with MSCs significantly reduced inflammatory cytokines and significantly increased adenosine triphosphate storage and various growth factors (endothelial growth factor, fibroblast growth factor 2 and transforming growth factor α).114 Sierra Parraga et al119 investigated the effect of perfusion fluid on the survival and function of MSCs. Although the perfusion fluid significantly reduced the capacity of MSCs to adhere to endothelial cells, it also increased proliferation after the cells adhere. In addition, they showed that the secretory profile of MSCs is not affected by perfusion.119 Since a large number of MSC are needed for NMP, Parraga et al investigated the impact of the freeze-thaw process on MSCs. Specifically, Sierra Parraga et al119 showed that the free-thaw process reduces survival and metabolism, increases oxidative stress, and impairs cell adherence. Pool et al113 fluorescently labeled MSCs to assess the localization and survival of MSCs during NMP in a porcine ESKP model. After 6 h of perfusion with 107 MSCs, small clusters of glomeruli showed positive staining for MSC, and these cells reached as far as the renal cortex.113

Yang et al110 explored the potential of using erythropoietin, a hormone with protective paracrine effects in the kidney, as a therapeutic agent during normothermic ESKP. In a porcine ESKP model, the addition of erythropoietin significantly suppressed inflammatory activity (caspase-3 and IL-1β) during 2 h of perfusion. Improved urine output was also observed as a result.110 The same group also examined the renoprotective effects of cyclic helix B peptide (CHBP), an erythropoietin derivative, in a similar porcine model.111 Unlike erythropoietin, CHBP does not cause erythropoiesis and its subsequential side effects. Similar to erythropoietin, CHBP improved urine output, in addition to renal blood flow and oxygen consumption.111

Tietjen et al112 recently demonstrated the potential of using anti-CD31 antibody to enhance the delivery of nanoparticles to endothelial cells of human kidney grafts. The accumulation of nanoparticles was increased by 5- to 10-fold by the addition of anti-CD31 antibodies.112 These nanoparticles can serve as “depots for long-term drug release” and can be used to deliver therapeutic agents specifically to the kidney endothelium. Other laboratories have also examined the potential of using nanoparticles to deliver antioxidative agents, antagonists to IRI mediators, and genetic material to reduce tissue damage during transplantation.120

Several other therapeutic agents have also been investigated to target specific pathways in IRI.121 Although these agents have not been tested in MP models yet, they represent promising MPTA agents in the future. Hydrogen sulfate (H2S) has known cytoprotective properties, such as mitigating oxidative stress and decreasing inflammation.122 Recently, a synthetic slow-releasing donor molecule (AP39) has been created for the delivery of H2S in organ transplant.123124 Streptokinase, a thrombolytic agent, has been shown to improve kidney microvasculature, when it is injected intraarterially into the kidneys.125126 Diannexin (a phosphatidylserine inhibitor), recombinant molecule resulting from the fusion of P-selectin glycoprotein ligand (PSGL) and human igG1(an inhibitor polymorphonuclear leukocyte recruitment), and I5NP (inhibitor of p53 expression) have also been shown to mitigate kidney IRI.127

Cardiac Machine Perfusion Therapeutics

Cardiovascular disease is currently the leading cause of death worldwide, and there are nearly 6.5 million adults in the United States who is suffering from end-stage heart failure.128 Although cardiac transplantation remains the gold standard for treating patients with heart failure, this procedure can lead to numerous posttransplant complications, such as graft dysfunction and rejection. Cardiac gene therapy has emerged as a promising approach to ameliorate IRI during transplantation and to recondition cardiac grafts to decrease the incidences of posttransplant graft dysfunction. Several studies have demonstrated the successful uptake of adeno-associated virus vector by myocytes during ex situ intracoronary administration.129130 Bishawi et al131 took this step further by administering adenoviral luciferase vectors during normothermic ex situ cardiac perfusion in a porcine transplantation model. After 2 h of NMP with intracoronary delivery of viral vectors, the donor hearts were transplanted into recipient pigs. Robust luciferase activity and protein expression were observed in all 4 cardiac chambers after 5 d of reperfusion.131

The addition of siRNA in cardiac NMP has also been explored. In a porcine ex situ perfusion model, Wei et al132 added siRNAs targeting inflammatory and apoptotic signal proteins, such as C3, nuclear factor κB-p56, caspase-8, and caspase-3 into the perfusate. Treated hearts demonstrated significantly reduced apoptosis and less structural damage compared with MP alone, in addition to improved left ventricular cardiac function.132 These successful applications of gene modulation during cardiac NMP opens the door to numerous other targeted therapies in cardiac transplantation.

CONCLUSION

The rapid advancements in MP of lung, liver, and kidney have allowed for the utilization of marginal grafts for patients who are in dire need of a lifesaving organ.133134 In turn, these advancements have also pushed for the exploration of potential therapeutic agents that may be used during the perfusion period. New advancements in MPTAs are particularly exciting because they offers several advantages compared with systemic treatment. First, they require a lower dosage of drugs to take effect; this is especially significant for drugs that require a weight-dependent dosage, such as siRNA. Second, MPTAs allow for a much more targeted method for delivering drugs with potential systemic side effects, such as MSCs and thrombolytic agents.

Currently, no MPTAs have been tested in randomized clinical trials. However, many promising MPTAs, especially in the field of lung transplantation, have been extensively tested in animal and discarded human organ models and are very close to reaching the stage of clinical trials. Some therapeutic agents, such as thrombolytic40,67 and antibacterial42 agents, have already been used to recondition discarded human grafts and led to successful transplantations. Since the success of clinical trials in kidney and liver MPs are recent, most MPTA studies in these fields are still in the animal model stage. More human studies, especially randomized trials, are needed in the future to solidify the therapeutic potential of MPTAs in these organ transplants.

REFERENCES

1. Organ Procurement And Transplantation Network National Data. 2019, Richmond, VA: United Network for Organ Sharing. Available at https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/. Accessed July 30, 2019
2. Busquets J, Xiol X, Figueras J, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation. 2001; 71:1765–1771. doi:10.1097/00007890-200106270-00011
3. Kawut SM, Reyentovich A, Wilt JS, et al. Outcomes of extended donor lung recipients after lung transplantation. Transplantation. 2005; 79:310–316. doi:10.1097/01.tp.0000149504.53710.ae
4. Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014; 515:431–435. doi:10.1038/nature13909
5. Petrenko A, Carnevale M, Somov A, et al. Organ preservation into the 2020s: the era of dynamic intervention. Transfus Med Hemother. 2019; 46:151–172. doi:10.1159/000499610
6. Rojas-Pena A, Bartlett RH. Ex situ organ preservation: the temperature paradigm. Transplantation. 2018; 102:554–556. doi:10.1097/TP.0000000000002081
7. Dutkowski P, Guarrera JV, de Jonge J, et al. Evolving trends in machine perfusion for liver transplantation. Gastroenterology. 2019; 156:1542–1547. doi:10.1053/j.gastro.2018.12.037
8. Muller X, Schlegel A, Kron P, et al. Novel real-time prediction of liver graft function during hypothermic oxygenated machine perfusion before liver transplantation. Ann Surg. 2019; 270:783–790. doi:10.1097/SLA.0000000000003513
9. Karimian N, Yeh H. Opportunities for therapeutic intervention during machine perfusion. Curr Transplant Rep. 2017; 4:141–148. doi:10.1007/s40472-017-0144-y
10. Hamaoui K, Gowers S, Sandhu B, et al. Development of pancreatic machine perfusion: translational steps from porcine to human models. J Surg Res. 2018; 223:263–274. doi: 10.1016/j.jss.2017.11.052
11. Leemkuil M, Lier G, Engelse MA, et al. Hypothermic oxygenated machine perfusion of the human donor pancreas. Transplant Direct. 2018; 4:e388. doi:10.1097/TXD.0000000000000829
12. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998; 351:24–27. doi: 10.1016/S0140-6736(97)06405-2
13. Israni AK, Zaun D, Rosendale JD, et al. OPTN/SRTR 2017 annual data report: deceased organ donation Am J Transplant. 2019; 19Suppl 2485–516. doi:10.1111/ajt.15280
14. de Perrot M, Liu M, Waddell TK, et al. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003; 167:490–511. doi:10.1164/rccm.200207-670SO
15. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011; 364:1431–1440. doi:10.1056/NEJMoa1014597
16. Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg. 2012; 144:1200–1206. doi:10.1016/j.jtcvs.2012.08.009
17. Fildes JE, Archer LD, Blaikley J, et al. Clinical outcome of patients transplanted with marginal donor lungs via ex vivo lung perfusion compared to standard lung transplantation. Transplantation. 2015; 99:1078–1083. doi: 10.1097/TP.0000000000000462
18. Mordant P, Nakajima D, Kalaf R, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation. J Heart Lung Transplant. 2016; 35:1245–1254. doi:10.1016/j.healun.2016.04.017
19. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009; 106:16357–16362. doi:10.1073/pnas.0907996106
20. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013; 187:751–760. doi:10.1164/rccm.201206-0990OC
21. McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014; 306:L809–L815. doi:10.1152/ajplung.00358.2013
22. Stone ML, Zhao Y, Robert Smith J, et al. Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. Respir Res. 2017; 18:212. doi: 10.1186/s12931-017-0704-9
23. Gennai S, Monsel A, Hao Q, et al. Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Transplant. 2015; 15:2404–2412. doi:10.1111/ajt.13271
24. Park J, Kim S, Lim H, et al. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia Thorax. 2019; 74:43–50. doi:10.1136/thoraxjnl-2018-211576
25. Martens A, Ordies S, Vanaudenaerde BM, et al. Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model. Stem Cell Res Ther. 2017; 8:159. doi:10.1186/s13287-017-0603-5
26. La Francesca S, Ting AE, Sakamoto J, et al. Multipotent adult progenitor cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. Transplant Res. 2014; 3:19. doi:10.1186/2047-1440-3-19
27. Stone ML, Sharma AK, Mas VR, et al. Ex vivo perfusion with adenosine A2A receptor agonist enhances rehabilitation of murine donor lungs after circulatory death. Transplantation. 2015; 99:2494–2503. doi:10.1097/TP.0000000000000830
28. Emaminia A, Lapar DJ, Zhao Y, et al. Adenosine A2A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg. 2011; 92:1840–1846. doi:10.1016/j.athoracsur.2011.06.062
29. Wagner CE, Pope NH, Charles EJ, et al. Ex vivo lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death. J Thorac Cardiovasc Surg. 2016; 151:538–545. doi:10.1016/j.jtcvs.2015.07.075
30. Huerter ME, Charles EJ, Downs EA, et al. Enteral access is not required for esophageal cancer patients undergoing neoadjuvant therapy. Ann Thorac Surg. 2016; 102:948–954. doi:10.1016/j.athoracsur.2016.03.041
31. Charles EJ, Kron IL. Which ischemic mitral valves should be repaired and how? Time will tell. J Thorac Cardiovasc Surg. 2017; 154:833. doi:10.1016/j.jtcvs.2017.05.006
32. Valenza F, Rosso L, Coppola S, et al. β-adrenergic agonist infusion during extracorporeal lung perfusion: effects on glucose concentration in the perfusion fluid and on lung function. J Heart Lung Transplant. 2012; 31:524–530. doi:10.1016/j.healun.2012.02.001
33. Kondo T, Chen F, Ohsumi A, et al. β2-adrenoreceptor agonist inhalation during ex vivo lung perfusion attenuates lung injury. Ann Thorac Surg. 2015; 100:480–486. doi:10.1016/j.athoracsur.2015.02.136
34. Hijiya K, Chen-Yoshikawa TF, Kondo T, et al. Bronchodilator inhalation during ex vivo lung perfusion improves posttransplant graft function after warm ischemia. Ann Thorac Surg. 2017; 103:447–453. doi:10.1016/j.athoracsur.2016.07.066
35. Inci I, Ampollini L, Arni S, et al. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. J Heart Lung Transplant. 2008; 27:1229–1236. doi:10.1016/j.healun.2008.07.027
36. Inci I, Hillinger S, Arni S, et al. Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an ex vivo lung perfusion system followed by transplantation. J Surg Res. 2013; 184:1143–1149. doi:10.1016/j.jss.2013.04.043
37. Khalifé-Hocquemiller T, Sage E, Dorfmuller P, et al. Exogenous surfactant attenuates lung injury from gastric-acid aspiration during ex vivo reconditioning in pigs. Transplantation. 2014; 97:413–418. doi:10.1097/01.TP.0000441320.10787.c5
38. Nakajima D, Liu M, Ohsumi A, et al. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration-induced donor lung injury. J Heart Lung Transplant. 2017; 36:577–585. doi:10.1016/j.healun.2016.11.010
39. Inci I, Zhai W, Arni S, et al. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors. J Heart Lung Transplant. 2007; 26:1054–1060. doi:10.1016/j.healun.2007.07.033
40. Inci I, Yamada Y, Hillinger S, et al. Successful lung transplantation after donor lung reconditioning with urokinase in ex vivo lung perfusion system. Ann Thorac Surg. 2014; 98:1837–1838. doi:10.1016/j.athoracsur.2014.01.076
41. Machuca TN, Cypel M, Bonato R, et al. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther. 2017; 28:757–765. doi:10.1089/hum.2016.070
42. Andreasson A, Karamanou DM, Perry JD, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Heart Lung Transplant. 2014; 33:910–916. doi:10.1016/j.healun.2013.12.023
43. Nakajima D, Cypel M, Bonato R, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016; 16:1229–1237. doi:10.1111/ajt.13562
44. Galasso M, Feld JJ, Watanabe Y, et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun. 2019; 10:481. doi:10.1038/s41467-018-08261-z
45. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009; 1:4ra9. doi:10.1126/scitranslmed.3000266
46. Yeung JC, Wagnetz D, Cypel M, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther. 2012; 20:1204–1211. doi:10.1038/mt.2012.57
47. Figueiredo C, Carvalho Oliveira M, Chen-Wacker C, et al. Immunoengineering of the vascular endothelium to silence MHC expression during normothermic ex vivo lung perfusion. Hum Gene Ther. 2019; 30:485–496. doi:10.1089/hum.2018.117
48. Lin H, Chen M, Tian F, et al. α1-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant. 2018; 37:656–666. doi:10.1016/j.healun.2017.09.019
49. Martens A, Boada M, Vanaudenaerde BM, et al. Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung perfusion evaluation. Transpl Int. 2016; 29:1237–1246. doi:10.1111/tri.12823
50. Mehaffey JH, Charles EJ, Narahari AK, et al. Increasing circulating sphingosine-1-phosphate attenuates lung injury during ex vivo lung perfusion. J Thorac Cardiovasc Surg. 2018; 156:910–917. doi:10.1016/j.jtcvs.2018.02.090
51. Harada M, Oto T, Otani S, et al. A neutrophil elastase inhibitor improves lung function during ex vivo lung perfusion. Gen Thorac Cardiovasc Surg. 2015; 63:645–651. doi:10.1007/s11748-015-0585-0
52. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007; 179:1855–1863. doi:10.4049/jimmunol.179.3.1855
53. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003; 100:8407–8411. doi:10.1073/pnas.1432929100
54. Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014; 32:116–125. doi:10.1002/stem.1504
55. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001; 344:665–671. doi:10.1056/NEJM200103013440908
56. Raghavendran K, Willson D, Notter RH. Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin. 2011; 27:525–559. doi:10.1016/j.ccc.2011.04.005
57. Schepp CP, Reutershan J. Bench-to-bedside review: adenosine receptors–promising targets in acute lung injury? Crit Care. 2008; 12:226. doi:10.1186/cc6990
58. Fernandez LG, Sharma AK, LaPar DJ, et al. Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2013; 145:1654–1659. doi:10.1016/j.jtcvs.2013.01.006
59. Gazoni LM, Walters DM, Unger EB, et al. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2010; 140:440–446. doi:10.1016/j.jtcvs.2010.03.002
60. LaPar DJ, Laubach VE, Emaminia A, et al. Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model. J Thorac Cardiovasc Surg. 2011; 142:887–894. doi:10.1016/j.jtcvs.2011.06.015
61. Valenza F, Rosso L, Pizzocri M, et al. The consumption of glucose during ex vivo lung perfusion correlates with lung edema. Transplant Proc. 2011; 43:993–996. doi:10.1016/j.transproceed.2011.01.122
62. McAuley DF, Frank JA, Fang X, et al. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med. 2004; 32:1470–1476. doi:10.1097/01.ccm.0000129489.34416.0e
63. Chen F, Nakamura T, Fujinaga T, et al. Protective effect of a nebulized beta2-adrenoreceptor agonist in warm ischemic-reperfused rat lungs. Ann Thorac Surg. 2006; 82:465–471. doi:10.1016/j.athoracsur.2006.01.010
64. Sakamoto J, Chen F, Nakajima D, et al. The effect of β-2 adrenoreceptor agonist inhalation on lungs donated after cardiac death in a canine lung transplantation model. J Heart Lung Transplant. 2012; 31:773–779. doi:10.1016/j.healun.2012.03.012
65. Sugimoto R, Date H, Sugimoto S, et al. Post-mortem administration of urokinase in canine lung transplantation from non-heart-beating donors. J Heart Lung Transplant. 2006; 25:1148–1153. doi:10.1016/j.healun.2006.07.005
66. Umemori Y, Date H, Uno K, et al. Improved lung function by urokinase infusion in canine lung transplantation using non-heart-beating donors. Ann Thorac Surg. 1995; 59:1513–1518. doi:10.1016/0003-4975(95)00188-q
67. Machuca TN, Hsin MK, Ott HC, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med. 2013; 188:878–880. doi:10.1164/rccm.201302-0368LE
68. Durand CM, Bowring MG, Thomas AG, et al. The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study. Ann Intern Med. 2018; 168:702–711. doi:10.7326/M17-2451
69. Cypel M, Feld JJ, Galasso M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial Lancet Respir Med. 2019; 8:192–201. doi:10.1016/S2213-2600(19)30268-1
70. Brüggenwirth IMA, Martins PN. RNA interference therapeutics in organ transplantation: the dawn of a new era. Am J Transplant. 2020; 20:931–941. doi:10.1111/ajt.15689
71. Haam S, Lee S, Paik HC, et al. The effects of hydrogen gas inhalation during ex vivo lung perfusion on donor lungs obtained after cardiac death. Eur J Cardiothorac Surg. 2015; 48:542–547. doi:10.1093/ejcts/ezv057
72. Nasralla D, Coussios CC, Mergental H, et al.; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018; 557:50–56. doi:10.1038/s41586-018-0047-9
73. Ravikumar R, Jassem W, Mergental H, et al. Liver transplantation after ex vivo normothermic machine preservation: a phase 1 (first-in-man) clinical trial. Am J Transplant. 2016; 16:1779–1787. doi:10.1111/ajt.13708
74. Selzner M, Goldaracena N, Echeverri J, et al. Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: first North American results. Liver Transpl. 2016; 22:1501–1508. doi:10.1002/lt.24499
75. Marecki H, Bozorgzadeh A, Porte RJ, et al. Liver ex situ machine perfusion preservation: a review of the methodology and results of large animal studies and clinical trials. Liver Transpl. 2017; 23:679–695. doi:10.1002/lt.24751
76. Nickkholgh A, Nikdad M, Shafie S, et al. Ex situ liver machine perfusion as an emerging graft protective strategy in clinical liver transplantation: the Dawn of a new era. Transplantation. 2019; 103:2003–2011. doi:10.1097/TP.0000000000002772
77. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2017 annual data report: liver Am J Transplant. 2019; 19Suppl 2184–283. doi:10.1111/ajt.15276
78. Linares-Cervantes I, Echeverri J, Cleland S, et al. Predictor parameters of liver viability during porcine normothermic ex situ liver perfusion in a model of liver transplantation with marginal grafts. Am J Transplant. 2019; 19:2991–3005. doi:10.1111/ajt.15395
79. Sutton ME, op den Dries S, Karimian N, et al. Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion. PLoS One. 2014; 9:e110642. doi:10.1371/journal.pone.0110642
80. Abudhaise H, Davidson BR, DeMuylder P, et al. Evolution of dynamic, biochemical, and morphological parameters in hypothermic machine perfusion of human livers: a proof-of-concept study. PLoS One. 2018; 13:e0203803. doi:10.1371/journal.pone.0203803
81. Laing RW, Mergental H, Yap C, et al. Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. BMJ Open. 2017; 7:e017733. doi:10.1136/bmjopen-2017-017733
82. Matton APM, de Vries Y, Burlage LC, et al. Biliary bicarbonate, pH, and glucose are suitable biomarkers of biliary viability during ex situ normothermic machine perfusion of human donor livers. Transplantation. 2019; 103:1405–1413. doi:10.1097/TP.0000000000002500
83. van Leeuwen OB, de Vries Y, Fujiyoshi M, et al. Transplantation of high-risk donor livers after ex situ resuscitation and assessment using combined hypo- and normothermic machine perfusion: a prospective clinical trial. Ann Surg. 2019; 270:906–914. doi:10.1097/SLA.0000000000003540
84. Verhoeven CJ, Farid WR, de Jonge J, et al. Biomarkers to assess graft quality during conventional and machine preservation in liver transplantation. J Hepatol. 2014; 61:672–684. doi:10.1016/j.jhep.2014.04.031
85. Watson CJE, Kosmoliaptsis V, Pley C, et al. Observations on the ex situ perfusion of livers for transplantation. Am J Transplant. 2018; 18:2005–2020. doi:10.1111/ajt.14687
86. Jamieson RW, Zilvetti M, Roy D, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 2011; 92:289–295. doi:10.1097/TP.0b013e318223d817
87. Liu Q, Berendsen T, Izamis ML, et al. Perfusion defatting at subnormothermic temperatures in steatotic rat livers. Transplant Proc. 2013; 45:3209–3213. doi:10.1016/j.transproceed.2013.05.005
88. Nagrath D, Xu H, Tanimura Y, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng. 2009; 11:274–283. doi:10.1016/j.ymben.2009.05.005
89. Echeverri J, Goldaracena N, Kaths JM, et al. Comparison of BQ123, epoprostenol, and verapamil as vasodilators during normothermic ex vivo liver machine perfusion. Transplantation. 2018; 102:601–608. doi:10.1097/TP.0000000000002021
90. Hara Y, Akamatsu Y, Maida K, et al. A new liver graft preparation method for uncontrolled non-heart-beating donors, combining short oxygenated warm perfusion and prostaglandin E1. J Surg Res. 2013; 184:1134–1142. doi:10.1016/j.jss.2013.04.030
91. Maida K, Akamatsu Y, Hara Y, et al. Short oxygenated warm perfusion with prostaglandin E1 administration before cold preservation as a novel resuscitation method for liver grafts from donors after cardiac death in a rat in vivo model. Transplantation. 2016; 100:1052–1058. doi:10.1097/TP.0000000000001127
92. Nassar A, Liu Q, Farias K, et al. Role of vasodilation during normothermic machine perfusion of DCD porcine livers. Int J Artif Organs. 2014; 37:165–172. doi:10.5301/ijao.5000297
93. Goldaracena N, Spetzler VN, Echeverri J, et al. Inducing hepatitis C virus resistance after pig liver transplantation-a proof of concept of liver graft modification using warm ex vivo perfusion. Am J Transplant. 2017; 17:970–978. doi:10.1111/ajt.14100
94. Gillooly AR, Perry J, Martins PN. First report of siRNA uptake (for RNA interference) during ex vivo hypothermic and normothermic liver machine perfusion. Transplantation. 2019; 103:e56–e57. doi:10.1097/TP.0000000000002515
95. Thijssen MF, Brüggenwirth IMA, Gillooly A, et al. Gene silencing with siRNA (RNA interference): a new therapeutic option during ex vivo machine liver perfusion preservation Liver Transpl. 2019; 25:140–151. doi:10.1002/lt.25383
96. Goldaracena N, Echeverri J, Spetzler VN, et al. Anti-inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation. Liver Transpl. 2016; 22:1573–1583. doi:10.1002/lt.24603
97. Rigo F, De Stefano N, Navarro-Tableros V, et al. Extracellular vesicles from human liver stem cells reduce injury in an ex vivo normothermic hypoxic rat liver perfusion model. Transplantation. 2018; 102:e205–e210. doi:10.1097/TP.0000000000002123
98. Beal EW, Kim JL, Reader BF, et al. [D-Ala2, D-Leu5] Enkephalin improves liver preservation during normothermic ex vivo perfusion. J Surg Res. 2019; 241:323–335. doi:10.1016/j.jss.2019.04.010
99. Yu Y, Cheng Y, Pan Q, et al. Effect of the selective NLRP3 inflammasome inhibitor mcc950 on transplantation outcome in a pig liver transplantation model with organs from donors after circulatory death preserved by hypothermic machine perfusion. Transplantation. 2019; 103:353–362. doi:10.1097/TP.0000000000002461
100. McCormack L, Petrowsky H, Jochum W, et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg. 2007; 246:940–6. discussion 946. doi:10.1097/SLA.0b013e31815c2a3f
101. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. J Hepatol. 2013; 59:1094–1106. doi: 10.1016/j.jhep.2013.06.017
102. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2017 annual data report: kidney Am J Transplant. 2019; 19(Suppl 2)19–123. doi:10.1111/ajt.15274
103. Hameed AM, Pleass HC, Wong G, et al. Maximizing kidneys for transplantation using machine perfusion: from the past to the future: a comprehensive systematic review and meta-analysis. Medicine (Baltimore). 2016; 95:e5083. doi:10.1097/MD.0000000000005083
104. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. Am J Transplant. 2013; 13:1246–1252. doi:10.1111/ajt.12179
105. Weissenbacher A, Lo Faro L, Boubriak O, et al. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am J Transplant. 2019; 19:178–192. doi:10.1111/ajt.14932
106. Hosgood SA, Barlow AD, Hunter JP, et al. Ex vivo normothermic perfusion for quality assessment of marginal donor kidney transplants. Br J Surg. 2015; 102:1433–1440. doi:10.1002/bjs.9894
107. Hosgood SA, Thompson E, Moore T, et al. Normothermic machine perfusion for the assessment and transplantation of declined human kidneys from donation after circulatory death donors. Br J Surg. 2018; 105:388–394. doi:10.1002/bjs.10733
108. Kaths JM, Hamar M, Echeverri J, et al. Normothermic ex vivo kidney perfusion for graft quality assessment prior to transplantation. Am J Transplant. 2018; 18:580–589. doi:10.1111/ajt.14491
109. Guzzi F, Knight SR, Ploeg RJ, et al. A systematic review to identify whether perfusate biomarkers produced during hypothermic machine perfusion can predict graft outcomes in kidney transplantation Transpl Int. 2020; 33:590–602. doi:10.1111/tri.13593
110. Yang B, Hosgood SA, Bagul A, et al. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol. 2011; 660:420–430. doi:10.1016/j.ejphar.2011.03.044
111. Yang C, Hosgood SA, Meeta P, et al. Cyclic helix B peptide in preservation solution and autologous blood perfusate ameliorates ischemia-reperfusion injury in isolated porcine kidneys. Transplant Direct. 2015; 1:e6. doi:10.1097/TXD.0000000000000515
112. Tietjen GT, Hosgood SA, DiRito J, et al. Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys Sci Transl Med. 2017; 9:eaam6764. doi:10.1126/scitranslmed.aam6764
113. Pool M, Eertman T, Sierra Parraga J, et al. Infusing mesenchymal stromal cells into porcine kidneys during normothermic machine perfusion: intact MSCs can be traced and localised to glomeruli Int J Mol Sci. 2019; 20:3607. doi:10.3390/ijms20143607
114. Brasile L, Henry N, Orlando G, et al. Potentiating renal regeneration using mesenchymal stem cells. Transplantation. 2019; 103:307–313. doi:10.1097/TP.0000000000002455
115. Hamaoui K, Gowers S, Boutelle M, et al. Organ pretreatment with cytotopic endothelial localizing peptides to ameliorate microvascular thrombosis and perfusion deficits in ex vivo renal hemoreperfusion models. Transplantation. 2016; 100:e128–e139. doi:10.1097/TP.0000000000001437
116. Gregorini M, Corradetti V, Pattonieri EF, et al. Perfusion of isolated rat kidney with mesenchymal stromal cells/extracellular vesicles prevents ischaemic injury. J Cell Mol Med. 2017; 21:3381–3393. doi:10.1111/jcmm.13249
117. Bhattacharjee RN, Richard-Mohamed M, Sun Q, et al. CORM-401 reduces ischemia reperfusion injury in an ex vivo renal porcine model of the donation after circulatory death. Transplantation. 2018; 102:1066–1074. doi:10.1097/TP.0000000000002201
118. Sedigh A, Nordling S, Carlsson F, et al. Perfusion of porcine kidneys with macromolecular heparin reduces early ischemia reperfusion injury. Transplantation. 2019; 103:420–427. doi:10.1097/TP.0000000000002469
119. Sierra Parraga JM, Rozenberg K, Eijken M, et al. Effects of normothermic machine perfusion conditions on mesenchymal stromal cells. Front Immunol. 2019; 10:765. doi:10.3389/fimmu.2019.00765
120. Yao CG, Martins PN. Nanotechnology applications in transplantation medicine Transplantation. 2019; 104:682–693. doi:10.1097/TP.0000000000003032
121. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant. 2006; 6:652–658. doi:10.1111/j.1600-6143.2005.01228.x
122. Soo E, Welch A, Marsh C, et al. Molecular strategies used by hibernators: potential therapeutic directions for ischemia reperfusion injury and preservation of human donor organs. Transplant Rev (Orlando). 2020; 34:100512. doi:10.1016/j.trre.2019.100512
123. Szczesny B, Módis K, Yanagi K, et al. AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Nitric Oxide. 2014; 41:120–130. doi:10.1016/j.niox.2014.04.008
124. Juriasingani S, Akbari M, Chan JY, et al. H2S supplementation: a novel method for successful organ preservation at subnormothermic temperatures. Nitric Oxide. 2018; 81:57–66. doi:10.1016/j.niox.2018.10.004
125. Gok MA, Shenton BK, Buckley PE, et al. How to improve the quality of kidneys from non-heart-beating donors: a randomised controlled trial of thrombolysis in non-heart-beating donors. Transplantation. 2003; 76:1714–1719. doi:10.1097/01.TP.0000093834.05766.FD
126. Yamauchi J, Schramm R, Richter S, et al. Improvement of microvascular graft equilibration and preservation in non-heart-beating donors by warm preflush with streptokinase. Transplantation. 2003; 75:449–453. doi:10.1097/01.TP.0000053404.67581.F4
127. Powell JT, Tsapepas DS, Martin ST, et al. Managing renal transplant ischemia reperfusion injury: novel therapies in the pipeline. Clin Transplant. 2013; 27:484–491. doi:10.1111/ctr.12121
128. Benjamin EJ, Blaha MJ, Chiuve SE, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135:e146–e603. doi:10.1161/CIR.0000000000000485
129. Miyagi N, Rao VP, Ricci D, et al. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant. 2008; 27:554–560. doi:10.1016/j.healun.2008.01.025
130. Raissadati A, Jokinen JJ, Syrjälä SO, et al. Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. Transpl Int. 2013; 26:1126–1137. doi:10.1111/tri.12182
131. Bishawi M, Roan JN, Milano CA, et al. A normothermic ex vivo organ perfusion delivery method for cardiac transplantation gene therapy. Sci Rep. 2019; 9:8029. doi:10.1038/s41598-019-43737-y
132. Wei J, Chen S, Xue S, et al. Blockade of inflammation and apoptosis pathways by siRNA prolongs cold preservation time and protects donor hearts in a porcine model. Mol Ther Nucleic Acids. 2017; 9:428–439. doi:10.1016/j.omtn.2017.10.020
133. Wadström J, Ericzon BG, Halloran PF, et al. Advancing transplantation: new questions, new possibilities in kidney and liver transplantation. Transplantation. 2017; 101(Suppl 2S):S1–S41. doi:10.1097/TP.0000000000001563
134. Weissenbacher A, Vrakas G, Nasralla D, et al. The future of organ perfusion and re-conditioning. Transpl Int. 2019; 32:586–597. doi:10.1111/tri.13441
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.